Avastin approved for lung cancer in Japan
This article was originally published in Scrip
Executive Summary
Chugai/Roche's VEGF-targeting antibody Avastin (bevacizumab) has been formally approved in Japan for the first-line treatment of unresectable advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).